Celldex Therapeutics, Inc. (CLDX) — SEC Filings
Celldex Therapeutics, Inc. (CLDX) — 36 SEC filings. Latest: 8-K (Apr 2, 2026). Includes 13 8-K, 10 SC 13G/A, 6 10-Q.
View Celldex Therapeutics, Inc. on SEC EDGAR
Overview
Celldex Therapeutics, Inc. (CLDX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 10, 2025: Celldex Therapeutics, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $177.4 million, up from $110.8 million in the same period of 2024. This 60.1% increase was primarily driven by a substantial rise in research and development (R&D) expenses,
Sentiment Summary
Across 36 filings, the sentiment breakdown is: 3 bullish, 2 bearish, 31 neutral. The dominant filing sentiment for Celldex Therapeutics, Inc. is neutral.
Filing Type Overview
Celldex Therapeutics, Inc. (CLDX) has filed 13 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 10 SC 13G/A, 3 SC 13G with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (36)
Risk Profile
Risk Assessment: Of CLDX's 25 recent filings, 2 were flagged as high-risk, 6 as medium-risk, and 17 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $1,424,000 |
| Net Income | -$177,440,000 |
| EPS | -$2.67 |
| Debt-to-Equity | 0.08 |
| Cash Position | $583,200,000 |
| Operating Margin | -140.0% |
| Total Assets | $648,439,000 |
| Total Debt | $50,076,000 |
Key Executives
- Chief Executive Officer
- December 31, 2023
- February 13, 2024
- Abigail P. Johnson
Industry Context
The biopharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Celldex Therapeutics focus on developing novel therapies, often targeting unmet medical needs. Success is heavily dependent on clinical trial outcomes and regulatory approvals, with a high failure rate for drug candidates. The competitive landscape is intense, with many companies vying for breakthroughs in areas like oncology and immunology.
Top Tags
biotech (7) · institutional-ownership (5) · Biotechnology (4) · 10-Q (4) · financial-reporting (4) · amendment (4) · 8-K (3) · financials (3) · financial-condition (3) · 8-k (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $177.4M | for the nine months ended September 30, 2025, a 60.1% increase from $110.8M in 2024 |
| Research and Development Expenses | $169.7M | for the nine months ended September 30, 2025, up 45.5% from $116.6M in 2024 |
| Total Revenues | $1.4M | for the nine months ended September 30, 2025, down from $5.8M in 2024 |
| Cash, Cash Equivalents and Marketable Securities | $583.2M | as of September 30, 2025, down from $725.3M at December 31, 2024 |
| Net Cash Used in Operating Activities | $147.0M | for the nine months ended September 30, 2025, up from $125.3M in 2024 |
| Barzolvolimab/Anti-KIT Program R&D Expense | $134.0M | for the nine months ended September 30, 2025, up from $88.6M in 2024 |
| Shares Outstanding | 66,449,471 | as of October 29, 2025 |
| Revenue | $0 | No revenue reported for Q2 2025 or H1 2025, consistent with prior periods. |
| Q2 2025 R&D Expenses | $29.5M | Decreased by 8.1% from $32.1 million in Q2 2024. |
| H1 2025 R&D Expenses | $59.1M | Decreased by 7.5% from $63.9 million in H1 2024. |
| Q2 2025 G&A Expenses | $8.1M | Increased by 6.6% from $7.6 million in Q2 2024. |
| H1 2025 G&A Expenses | $16.0M | Increased by 6.0% from $15.1 million in H1 2024. |
| Reporting Period End Date | 2025-03-31 | Indicates the end of the financial quarter being reported. |
| Filing Date | 20250508 | The date the 10-Q was officially submitted to the SEC. |
| Fiscal Year End | 2024 | Information pertains to the fiscal year ending December 31, 2024. |
Forward-Looking Statements
- {"claim":"Vanguard will maintain a significant, passive stake in Celldex Therapeutics for the foreseeable future.","entity":"The Vanguard Group","targetDate":"December 2024","confidence":"high"}
- {"claim":"Celldex Therapeutics' stock price may experience increased stability due to Vanguard's substantial ownership.","entity":"Celldex Therapeutics Inc.","targetDate":"June 2024","confidence":"medium"}
- {"claim":"Other institutional investors may increase their positions in Celldex Therapeutics, following Polar Capital's lead.","entity":"Celldex Therapeutics, Inc.","targetDate":"Q2 2024","confidence":"medium"}
- {"claim":"Celldex Therapeutics' stock price may experience a slight positive bump due to increased institutional interest.","entity":"Celldex Therapeutics, Inc.","targetDate":"February 2024","confidence":"low"}
- {"claim":"FMR LLC will maintain a significant ownership stake in Celldex Therapeutics for the foreseeable future.","entity":"FMR LLC","targetDate":"12-2024","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Celldex Therapeutics, Inc. (CLDX)?
Celldex Therapeutics, Inc. has 36 recent SEC filings from Jan 2024 to Apr 2026, including 13 8-K, 10 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CLDX filings?
Across 36 filings, the sentiment breakdown is: 3 bullish, 2 bearish, 31 neutral. The dominant sentiment is neutral.
Where can I find Celldex Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Celldex Therapeutics, Inc. (CLDX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Celldex Therapeutics, Inc.?
Key financial highlights from Celldex Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CLDX?
The investment thesis for CLDX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Celldex Therapeutics, Inc.?
Key executives identified across Celldex Therapeutics, Inc.'s filings include Chief Executive Officer, December 31, 2023, February 13, 2024, Abigail P. Johnson.
What are the main risk factors for Celldex Therapeutics, Inc. stock?
Of CLDX's 25 assessed filings, 2 were flagged high-risk, 6 medium-risk, and 17 low-risk.
What are recent predictions and forward guidance from Celldex Therapeutics, Inc.?
Recent forward-looking statements from Celldex Therapeutics, Inc. include guidance on {"claim":"Vanguard will maintain a significant, passive stake in Celldex Therapeutics for the foreseeable future.","enti and 4 other predictions.